UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 6-K

                    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT
                         TO RULE 13A-16 OR 15D-16 UNDER
                       THE SECURITIES EXCHANGE ACT OF 1934

For the month of:  April, 2006

Commission File Number:  000-50393

                                 NEUROCHEM INC.

                          275 Armand-Frappier Boulevard
                                  Laval, Quebec
                                     H7V 4A7


Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40 F.   Form 20-F [ ] Form 40-F [X]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1):

                                                                  Yes [ ] No [X]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7):

                                                                  Yes [ ] No [X]

Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g-3 under the Securities Exchange Act of 1934.

                                                                  Yes [ ] No [X]

If "Yes" is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b):

                                   SIGNATURES:

       Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.


                                     NEUROCHEM INC.
April 24, 2006


                                     By: /s/ David Skinner
                                         ---------------------------------------
                                         David Skinner
                                         General Counsel and Corporate Secretary





                                                   NEUROCHEM INC.
                                                   275 Armand-Frappier Blvd.
[NEUROCHEM(LOGO)]                                  Laval, Quebec, Canada H7V 4A7
________________________________________________________________________________

For further information, please contact:

Lise Hebert, PhD                                         Tel: 1-450-680-4570
Vice President, Corporate Communications                 lhebert@neurochem.com
                                                         ---------------------

                  NEUROCHEM PRESENTS AN UPDATE ON TRAMIPROSATE
             (ALZHEMED(TM)) PROGRAM FOR THE TREATMENT OF ALZHEIMER'S
           DISEASE AT 9TH INTERNATIONAL GENEVA/SPRINGFIELD SYMPOSIUM
                        ON ADVANCES IN ALZHEIMER THERAPY


LAVAL, QUEBEC, APRIL 24, 2006 -- Neurochem, Inc. (NASDAQ: NRMX, TSX: NRM). --
Paul S. Aisen, M.D., Professor of Neurology and Medicine at Georgetown
University Medical Center, and principal investigator in the United States of
the ongoing Phase III clinical trial for tramiprosate (Alzhemed(TM)) presented
an update on Neurochem's investigational product candidate for the treatment of
Alzheimer's disease (AD). The presentation by Dr. Aisen took place on April 22,
in Geneva, Switzerland, at the 9th International Geneva/Springfield Symposium on
Advances in Alzheimer Therapy.

The data from the open-label extension study of the Phase II clinical trial for
tramiprosate (Alzhemed(TM)), involving mild-to-moderate AD patients, continues
to show clinically significant benefits on cognitive and global performance
measures, with stabilization of the disease in a proportion of mild patients
(four out of nine) after three years of treatment. Furthermore, Dr. Aisen
presented for the first time further results on the mechanism of action of
tramiprosate (Alzhemed(TM)). In addition to the capability of tramiprosate
(Alzhemed(TM)) to bind to soluble amyloid (beta) (A(beta)) peptide and interfere
with the amyloid cascade, data from in vitro studies have shown that
tramiprosate (Alzhemed(TM)) has a protective effect on neuronal cells against
A(beta) peptide-induced toxicity and cell death. Tramiprosate (Alzhemed(TM))
decreases A(beta)42-induced cell death and DNA damage in neuronal cell cultures
by 38% (p-value < 0.01). A copy of the presentation is available upon request.

"Overall, the Alzhemed(TM) program is very exciting. The fact that this product
can reduce amyloid accumulation, a major culprit in Alzheimer's disease, and
provide a protective effect against amyloid-induced toxicity to brain cells is
encouraging," said Dr. Aisen. "Developing a successful treatment to slow the
progression of this disease, which today remains an unmet medical need, would be
a major advance in the fields of neurology and age-related illnesses," he
concluded.






ABOUT THE PHASE III CLINICAL TRIALS FOR TRAMIPROSATE (ALZHEMED(TM))

Neurochem is currently conducting a randomized, double-blind, placebo-controlled
and parallel designed 18-month Phase III clinical trial in 1,052
mild-to-moderate AD patients, which is being carried out at close to 70 clinical
sites across the United States and Canada. To date, more than 50 patients have
completed the trial and more than 500 patients have completed 12 months on study
medication. The trial is now scheduled to be completed by January 2007. All
patients who complete the North American Phase III clinical trial will be
offered the opportunity to receive tramiprosate (Alzhemed(TM)) in an open-label
extension study. As announced previously, this open-label extension study will
be initiated in the second quarter of 2006.

Neurochem is also actively advancing an 18-month Phase III clinical trial for
tramiprosate (Alzhemed(TM)) in Europe, which was initiated in September 2005.
The ongoing European Phase III clinical trial, a multi-center, international,
randomized, double-blind, placebo-controlled and parallel designed study, to
investigate the safety and efficacy of tramiprosate (Alzhemed(TM)) in some 930
mild-to-moderate AD patients, is progressing on schedule. Enrollment is brisk
with more than 230 patients enrolled in the clinical trial and enrollment
expected to be completed in the fall of 2006.

ABOUT TRAMIPROSATE (ALZHEMED(TM))

Tramiprosate (Alzhemed(TM)) is a small, orally-administered molecule known as an
amyloid (beta) antagonist that crosses the blood-brain-barrier, binds to soluble
A(beta) peptide and interferes with the amyloid cascade, inhibits A(beta)
protein deposition in the brain and provides protection against A(beta)-induced
neurotoxicity.

ABOUT ALZHEIMER'S DISEASE

Alzheimer's disease (AD) is a progressive form of dementia associated with
specific brain pathologies. It impairs a person's cognitive and motor functions
and gradually destroys the brain.

AD is the most common cause of dementia in our aging population. Almost 5
million individuals in the United States alone currently suffer from the
condition. The U.S. Alzheimer's Association estimates that by 2025, over 22
million people worldwide will be afflicted.

According to a report commissioned by the U.S. Alzheimer's Association, AD costs
American businesses approximately US$61 billion a year. That price tag includes
US$24.6 billion for direct health care of Alzheimer's patients and US$36.5
billion to cover costs related to caregivers of AD patients, including lost
productivity, absenteeism and worker replacement.


ABOUT NEUROCHEM

Neurochem is focused on the development and commercialization of innovative
therapeutics to address critical unmet medical needs. Eprodisate (Fibrillex(TM))
is designated as an orphan drug, is a Fast Track product candidate and is also
part of FDA Continuous Marketing Application Pilot 1 and Pilot 2 programs. The
FDA designated



the eprodisate (Fibrillex(TM)) new drug application for priority review.
Tramiprosate (Alzhemed(TM)), for the treatment of Alzheimer's disease, is
currently in Phase III clinical trials in both North America and Europe, and
tramiprosate (Cerebril(TM)), for the prevention of Hemorrhagic Stroke caused by
Cerebral Amyloid Angiopathy, has completed a Phase IIa clinical trial.

TO CONTACT NEUROCHEM

For additional information on Neurochem and its drug development programs,
please call the North American toll-free number 1-877-680-4500 or visit our Web
Site at www.neurochem.com.


This news release contains forward-looking statements regarding tramiprosate
(Alzhemed(TM)), as well as regarding continuing and further development efforts.
These statements are based on the current analysis and expectations of
management. Drug development necessarily involves numerous risks and
uncertainties, which could cause actual results to differ materially from this
current analysis and these expectations. Analysis regarding the results of
clinical trials may not provide definitive results regarding safety,
tolerability or therapeutic benefits. Even if all the endpoints sought in the
clinical trials were met (which is not certain), there is no certainty that
regulators would ultimately approve Alzhemed(TM) for sale to the public. Risks
and uncertainties may include: failure to demonstrate the safety, tolerability
and efficacy of our product, the expense and uncertainty of obtaining regulatory
approval, including from the FDA, and the possibility of having to conduct
additional clinical trials. Further, even if regulatory approval is obtained,
therapeutic products are generally subject to: stringent on-going governmental
regulation, challenges in gaining market acceptance, and competition. Neurochem
does not undertake any obligation to publicly update its forward-looking
statements, whether as a result of new information, future events, or otherwise.
Please see the Annual Information Form for further risk factors that might
affect the Company and its business.